首页 | 本学科首页   官方微博 | 高级检索  
检索        

不同起始剂量甲巯咪唑治疗Graves病的疗效
引用本文:戴红,吴蕾,徐丽君,崔屹,宋宇,栗偲平,朱红霞,贺威,马英,佟珊珊,王雪,崔娟红.不同起始剂量甲巯咪唑治疗Graves病的疗效[J].武警医学,2017,28(10):977-979.
作者姓名:戴红  吴蕾  徐丽君  崔屹  宋宇  栗偲平  朱红霞  贺威  马英  佟珊珊  王雪  崔娟红
作者单位:1.110034 沈阳,武警辽宁总队医院内二科; 2.100039 北京,武警总医院
摘    要: 目的 探讨甲巯咪唑最佳的起始剂量治疗方案。方法 病例选自在武警辽宁总队医院门诊就诊的Graves病初诊或复发患者,随机分为两组,A组135例(甲巯咪唑15mg,1次/d)和B组110例(甲巯咪唑10 mg,3次/d),随访12周,比较两组的疗效及不良反应发生率。结果 (1)A组患者依从性达到91.9%,明显好于B组(80.9%);(2)治疗4周、8周及12周后甲状腺激素降至正常的比率在A组分别为62.1%、83.6%和89.7% ,B组分别为65.9%, 84.4% 和88.3%,无统计学差异;(3)药物不良反应发生率在A组为 5.9%,B组为10.9%;(4)甲状腺肿大达Ⅲ度(OR=12.529)或FT4显著升高达正常值的4倍以上(OR=9.117)的患者采用甲巯咪唑小剂量每日一次顿服法疗效欠佳。结论 初始治疗采用甲巯咪唑小剂量15 mg日一次顿服法对大多数Graves病患者安全有效,但对于甲状腺Ⅲ度肿大或甲状腺激素水平显著升高者起始治疗量10 mg每日3次方法更为适合。

关 键 词:Graves病  甲状腺功能亢进症  抗甲状腺药物  甲巯咪唑  

Initial treatment of thyrotoxic Graves’ disease with methimazole at different dosages
DAI Hong,WU Lei,XU Lijun,CUI Yi,SONG Yu,LI Siping,ZHU Hongxia,HE Wei,MA Ying,TONG Shanshan,WANG Xue,CUI Juanhong.Initial treatment of thyrotoxic Graves’ disease with methimazole at different dosages[J].Medical Journal of the Chinese People's Armed Police Forces,2017,28(10):977-979.
Authors:DAI Hong  WU Lei  XU Lijun  CUI Yi  SONG Yu  LI Siping  ZHU Hongxia  HE Wei  MA Ying  TONG Shanshan  WANG Xue  CUI Juanhong
Institution:1.Liaoning Provincial Corps Hospital, Chinese People’s Armed Police Force, Shenyang 110034, China; 2.General Hospital of Chinese People’s Armed Police Force,Beijing 100039,China
Abstract:Objective To compare the therapeutic effect of methimazole 15 mg/d and 30 mg/d for thyrotoxic Graves’ disease and to observe adverse reactions among newly diagnosed patients of this disease. MethodsTwo hundred and forty-five cases of Graves disease were randomly assigned to two therapy groups in a prospective study. Each patient in Group A(n=135) was given 15mg methimazole once daily in the morning while Group B(n=110) was given 10 mg methimazole three times a day. A follow-up study followed methimazole treatment at different initial dosages among all the participants. The remission rate and frequency of adverse effects were measured after 4, 8 and 12 weeks of treatment.Results (1)The rate of compliance with methimazole was 91.9% in Group A, which was significantly higher than 80.9% in Group B. (2) No remarkable difference of efficiency in normalizing FT4 and FT3 was observed between the two groups at the 4th, 8th and 12th week (62.1%, 83.6% and 89.7% in Group A compared with 65.9%, 84.4% and 88.3% in Group B). (3) The incidence of adverse reactions was 5.9% in Group A and 10.9% in Group B. (4)Thyroid enlargement of Ⅲ degree(OR=12.529) or four-time increase of serum FT4(OR=9.117)was a risk factor that influenced the treatment outcome of 15 mg methimazole once a day.Conclusions In the initial treatment ofg thyrotoxic Graves’ disease, 15 mg methimazole once a day is safe and effective for most patients, but for cases with thyroid enlargement of Ⅲ degree or significant elevation of thyroid hormone,10 mg methimazole three times a day is preferable.
Keywords:Graves disease  hyperthyroidism  antithyroid drug  methimazole  
点击此处可从《武警医学》浏览原始摘要信息
点击此处可从《武警医学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号